Retifanlimab

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process. William Heiden, Chairman of the Board of Directors said, “Scott was a co-founder of MacroGenics twenty-four years ago and the Company has achieved many milestones under his leadership – including several partnered or company-owned FDA approved monoclonal antibody therapeutics developed by the company. On behalf of the Board, I want to thank Scott for his incredible dedication to the Company’s mission of discovering and developing novel therapeutics to improve patient care.” Mr. Heiden continued, “Today, MacroGenics has several innovative antibody-based therapeutics in development for the treatment of cancer, as well as significant alliances with leading pharmaceutical and biotechnology companies to develop and commercialize novel therapeutics. The Company today has a broad portfolio of promising assets and a strong balance sheet, and the Board and Scott agreed that this is the right time to transition to our next phase of leadership. We look forward to continuing to benefit from his perspectives as an advisor and shareholder.” “I am proud of our many achievements since our founding in 2000, in which we built a fully integrated, science-focused biotechnology company and have been successful in discovering, developing, manufacturing, and commercializing novel immunotherapeutics derived from our proprietary Fc-engineered antibody, bi-specific DART molecule, and antibody drug conjugate (ADC) technologies,” said Dr. Koenig. “Since the company’s IPO in 2013, we were able to fund a significant part of the development portfolio through the achievement of over $1 billion of non-dilutive capital via partnerships. Thanks to the incredible passion and dedication of the people at MacroGenics, three novel therapeutics from our pipeline advanced to approval, including MARGENZA® and ZYNYZ® to treat patients with cancer, and TZIELD® for individuals with early-stage Type 1 diabetes, and we have advanced a rich portfolio of clinical and preclinical molecules in development. I am confident that MacroGenics is well positioned in its current mission to address the significant unmet medical needs of patients with cancer. I look forward to continuing to support the Company in its work to achieve its key strategic objectives and create value for all our stakeholders.” About MacroGenics, Inc. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of final safety and efficacy data, including mature median rPFS and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, especially timing and results of mature median radiographic progression-free survival, other efficacy and safety data with respect to vobramitamab duocarmazine; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. ###

点击蓝字 关注我们 2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia Congress 2024）将于当地时间12月6日~8日在新加坡召开。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，近日在官方网站正式公布本次大会的摘要题目及作者信息。肿瘤瞭望小编带您先睹为快，一览胸部肿瘤领域入选优选口头报告（Proffered Paper）和微型口头报告（Mini Oral）的临床研究。 1 优选口头报告（Proffered Paper） 摘要号：LBA8 英文标题：Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study 中文标题：阿替利珠单抗+卡铂/紫杉醇治疗转移性或复发性胸腺癌的II期临床试验：Marble研究 讲者：Tomoyasu Mimori (日本) 摘要号：625O 英文标题：Efficacy and safety of Lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-controlled multicenter phase II trial 中文标题：Lucitanib在晚期复发或转移性胸腺癌二线或后续治疗中的疗效和安全性：一项随机、双盲、安慰剂对照的多中心II期试验 讲者：方文涛（上海交通大学医学院附属胸科医院） 摘要号：LBA5 英文标题：Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of Beamion LUNG-1 中文标题：Zongertinib治疗HER2突变型NSCLC患者：Beamion LUNG-1的最新分析讲者：Noboru Yamamoto (日本) 摘要号：LBA6 英文标题：PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT) 中文标题：PACIFIC-5：针对同步或序贯放化疗（cCRT或sCRT）后未出现进展不可切除III期NSCLC患者进行巩固性度伐利尤单抗治疗的III期研究 讲者：吴一龙（广东省人民医院） 摘要号：LBA7 英文标题：Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): a pooled analysis of TROPION-Lung01 and TROPION-Lung05 中文标题：Dato-DXd对既往接受过治疗的EGFR突变晚期非小细胞肺癌患者的疗效和安全性：TROPION-Lung01和TROPION-Lung05的汇总分析 讲者：Myung-Ju Ahn (韩国) 2 微型口头报告（Mini Oral） 摘要号：626MO 英文标题：Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis of patients from the Asia region in the phase 2 DeLLphi-301 study 中文标题：Tarlatamab治疗既往接受过治疗的小细胞肺癌：II期DeLLphi-301研究中亚洲地区患者的亚组分析 讲者：Hiroaki Akamatsu (日本) 摘要号：627MO 英文标题：POD1UM-304: Phase 3 Study of Retifanlimab Plus Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Therapy For Nonsquamous or Squamous Metastatic Non–Small Cell Lung Cancer (mNSCLC) 中文标题：POD1UM-304：Retifanlimab+铂类化疗作为非鳞或鳞状转移性非小细胞肺癌一线疗法的III期研究 讲者：陆舜(上海交通大学医学院附属胸科医院) 摘要号：614MO 英文标题：A Phase Ⅱ Study of Becotatug (JMT101) in Combination with Osimertinib (Osi) in Patients (pts) with classical EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (BOOSTER Study) 中文标题：Becotatug联合奥希替尼治疗经典型EGFR突变非小细胞肺癌患者的Ⅱ期BOOSTER临床研究 讲者：张力(中山大学肿瘤防治中心) 摘要号：630MO 英文标题：First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort 中文标题：一线奥希替尼±铂类-培美曲塞化疗治疗EGFR突变晚期非小细胞肺癌：FLAURA2亚洲队列 讲者：James Chih-Hsin Yang (中国台湾) 摘要号：628MO 英文标题：Comparing Subcutaneous vs Intravenous Amivantamab with Lazertinib in EGFR-Mutated Advanced NSCLC: Analysis of Asian Patients From PALOMA-3 中文标题：比较皮下注射vs静脉注射Amivantamab联合Lazertinib治疗EGFR突变晚期NSCLC：对PALOMA-3亚洲患者的分析 讲者：Se-Hoon Lee (韩国) 摘要号：629MO 英文标题：ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC) 中文标题：ALESIA研究7年随访更新：阿来替尼vs克唑替尼在未经治疗的晚期ALK+非小细胞肺癌亚洲患者中的疗效对比 讲者：周彩存(上海市东方医院) （来源：《肿瘤瞭望》编辑部） 声 明 凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。